TELO - Bathi resik saben saham (EPS TTM) Telomir Pharmaceuticals Inc

The production cycle of Telomir Pharmaceuticals (TELO) relies on external CDMO plants, which minimizes operational risks. The company's rolling annual profit per share, as shown in this chart from GURU.Markets, reflects a trend where the indicator level stands at -0.89. This metric accompanies the search for telomere regeneration methods to treat rare pathologies and the development of innovative drugs aimed at achieving longevity.
Telomir Pharma (TELO) - rincian metrik lan laporan keuangan

Telomir Pharmaceuticals (TELO) operates in the high-risk biomedicine sector, investing in telomere research. This chart, displaying net earnings per share over the last four quarters, measures the portion of profit allocated to each security per year. This price action reflects the actual efficiency of the business capitalization. For preclinical startups, this indicator often signals development costs. The securities belong to a speculative asset class.